<DOC>
	<DOCNO>NCT01440387</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GlaxoSmithKline ( GSK ) Biologicals ' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV adult 18 year age old .</brief_summary>
	<brief_title>A Study Immunogenicity Safety GSK Biologicals ' Influenza Vaccine FLU-Q-QIV Adults Aged 18 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject Male female adult , 18 year age older stable health determine investigator 's clinical examination assessment subject ' medical history . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination Administration influenza vaccine within 6 month precede study start plan use vaccine study period . Administration vaccine ( ) within 30 day prior study enrolment study period . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Acute disease and/or fever time enrolment . Significant acute chronic , uncontrolled medical psychiatric illness . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , base history physical examination . Insulindependent diabetes mellitus . Presence blood dyscrasia , include hemoglobinopathy myelo lymphoproliferative disorder . Chronic administration immunosuppressant immunemodifying drug within six month prior study vaccine dose . A history demyelinate disease include Multiple Sclerosis GuillainBarr√© syndrome . Presence active neurological disorder . History chronic alcohol abuse and/or drug abuse deem investigator render potential subject unable/unlikely provide accurate safety report . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g . lowdose aspirin , without clinically apparent bleeding tendency eligible Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent FLUQQIV and/or history anaphylactic type reaction consumption egg , and/or reaction product contain mercury . A history severe adverse reaction previous influenza vaccination . Pregnant and/or lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Phase III</keyword>
	<keyword>Seasonal influenza</keyword>
</DOC>